Behavioural phenotyping of APPswe/PS1δE9 mice: Age-rrelated changes and effect of long-term paroxetine treatment

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Olesen, Louise Ørum ^a   Bouzinova, Elena V ^a   Severino, Maurizio ^b   Sivasaravanaparan, Mithula ^b   Hasselstrøm, Jørgen Bo ^a   Finsen, Bente ^b   Wiborg, Ove ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PAROXETINE; SEROTONIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1;

AGGRESSIVENESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR ASSESSMENT; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE REDUCTION; ELEVATED PLUS MAZE TEST; IMMUNOHISTOCHEMISTRY; LOCOMOTION; LONG TERM CARE; LONGITUDINAL STUDY; MOUSE; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; RISK ASSESSMENT; SOCIAL INTERACTION TEST; TREATMENT DURATION; TREATMENT RESPONSE; AGING; ALZHEIMER DISEASE; ANIMAL; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; MALE; MAZE TEST; MEMORY DISORDERS; METABOLISM; SOCIAL BEHAVIOR; TRANSGENIC MOUSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; PAROXETINE; PRESENILIN-1; SOCIAL BEHAVIOR;

EID: 84994659850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165144     Document Type: Article

References (52)

1. Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement. 2013; 9(5):602-8. Epub 2013/04/09. doi: 10.1016/j.jalz.2012.12.001 PMID: 23562430; PubMed Central PMCID: PMCPMC3766403.
2. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Science translational medicine. 2011; 3(77):77sr1. Epub 2011/04/08. doi: 10.1126/scitranslmed.3002369 PMID: 21471435; PubMed Central PMCID: PMCPMC3130546.
3. Masters MC, Morris JC, Roe CM. "Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis. Neurology. 2015; 84(6):617-22. Epub 2015/01/16. doi: 10.1212/wnl.0000000000001238 PMID: 25589671; PubMed Central PMCID: PMCPMC4335988.
4. Ringman JM, Liang LJ, Zhou Y, Vangala S, Teng E, Kremen S, et al. Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network. Brain. 2015; 138(Pt 4):1036-45. Epub 2015/02/18. doi: 10.1093/brain/awv004 PMID: 25688083.
5. Hendricksen M, Thomas AJ, Ferrier IN, Ince P, O'Brien JT. Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am J Psychiatry. 2004; 161(6):1096-102. Epub 2004/06/01. PMID: 15169699. doi: 10.1176/appi.ajp.161.6.1096
6. Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, et al. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care. Neurosci Biobehav Rev. 2013; 37(8):1363-79. Epub 2013/05/28. doi: 10.1016/j.neubiorev.2013.05.008 PMID: 23707776.
7. Vermeiren Y, Van Dam D, Aerts T, Engelborghs S, De Deyn PP. Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiol Aging. 2014; 35(12):2691-700. Epub 2014/07/07. doi: 10.1016/j.neurobiolaging. 2014.05.031 PMID: 24997673.
8. Madsen K, Neumann WJ, Holst K, Marner L, Haahr MT, Lehel S, et al. Cerebral serotonin 4 receptors and amyloid-beta in early Alzheimer's disease. Journal of Alzheimer's disease: JAD. 2011; 26(3):457-66. Epub 2011/06/16. doi: 10.3233/jad-2011-110056 PMID: 21673407.
9. Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging. 2003; 24(1):1-23. Epub 2002/12/21. PMID: 12493547.
10. Rodriguez JJ, Noristani HN, Verkhratsky A. The serotonergic system in ageing and Alzheimer's disease. Prog Neurobiol. 2012; 99(1):15-41. Epub 2012/07/07. doi: 10.1016/j.pneurobio.2012.06.010 PMID: 22766041.
11. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia. 2005; 43(3):442-9. Epub 2005/02/15. doi: 10.1016/j.neuropsychologia.2004.06.007 PMID: 15707619.
12. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2008; 28 (51):13805-14. Epub 2008/12/19. doi: 10.1523/jneurosci.4218-08.2008 PMID: 19091971.
13. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue {beta}-amyloid peptide in vivo: evidence for augmentation of a 42-specific {gamma} secretase. Human Molecular Genetics. 2004; 13(2):159-70. doi: 10.1093/hmg/ddh019 PMID: 14645205
14. Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Paulson OB, et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging. 2008; 29(12):1830-8. Epub 2007/06/05. doi: 10.1016/j.neurobiolaging.2007.04.011 PMID: 17544547.
15. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011; 108(36):14968-73. Epub 2011/08/30. doi: 10.1073/pnas.1107411108 PMID: 21873225; PubMed Central PMCID: PMC3169155.
16. Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice. Science translational medicine. 2014; 6(236):236re4. Epub 2014/05/16. doi: 10.1126/scitranslmed.3008169 PMID: 24828079; PubMed Central PMCID: PMCPmc4269372.
17. Emilsson JF, Andreasson U, Blennow K, Eriksson E, Zetterberg H. Comment on "An antidepressant decreases CSF Abeta production in healthy individuals and in transgenic AD mice". Science translational medicine. 2014; 6(268):268le5. Epub 2014/12/30. doi: 10.1126/scitranslmed.3010053 PMID: 25540322.
18. Nelson RL, Guo Z, Halagappa VM, Pearson M, Gray AJ, Matsuoka Y, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007; 205(1):166-76. Epub 2007/03/21. doi: 10.1016/j.expneurol. 2007.01.037 PMID: 17368447; PubMed Central PMCID: PMCPMC1979096.
19. Romano A, Pace L, Tempesta B, Lavecchia AM, Macheda T, Bedse G, et al. Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2015; 18(4). Epub 2015/01/23. doi: 10.1093/ijnp/pyu020 PMID: 25609597.
20. Babcock AA, Ilkjaer L, Clausen BH, Villadsen B, Dissing-Olesen L, Bendixen AT, et al. Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice. Brain Behav Immun. 2015. Epub 2015/03/17. doi: 10.1016/j.bbi.2015.03.006 PMID: 25774009.
21. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, et al. Amyloid Pathology Is Associated with Progressive Monoaminergic Neurodegeneration in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Neuroscience. 2008; 28(51):13805-14. doi: 10.1523/JNEUROSCI.4218-08.2008 PMID: 19091971
22. Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sanchez C, Haddjeri N. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007; 10(1):31-40. Epub 2006/02/02. doi: 10.1017/s1461145705006462 PMID: 16448580.
23. Jimenez AJ, Garcia-Fernandez JM, Gonzalez B, Foster RG. The spatio-temporal pattern of photoreceptor degeneration in the aged rd/rd mouse retina. Cell and tissue research. 1996; 284(2):193-202. Epub 1996/05/01. PMID: 8625386.
24. Garcia MF, Gordon MN, Hutton M, Lewis J, McGowan E, Dickey CA, et al. The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice. Neuroreport. 2004; 15(1):73-7. Epub 2004/04/27. PMID: 15106834.
25. Hasselstrom J. Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 2011; 879(1):123-8. Epub 2010/12/18. doi: 10.1016/j.jchromb.2010.11.024 PMID: 21163713.
26. Budaev SV. Using Principal Components and Factor Analysis in Animal Behaviour Research: Caveats and Guidelines. Ethology. 2010; 116(5):472-80. doi: 10.1111/j.1439-0310.2010.01758.x
27. Abdi H, Williams LJ. Principal component analysis. Wiley Interdisciplinary Reviews: Computational Statistics. 2010; 2(4):433-59. doi: 10.1002/wics.101
28. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. Epub 1991/10/01. doi: 10.1002/ana.410300410 PMID: 1789684.
29. Arai H, Ichimiya Y, Kosaka K, Moroji T, Iizuka R. Neurotransmitter changes in early- and late-onset Alzheimer-type dementia. Progress in neuro-psychopharmacology & biological psychiatry. 1992; 16 (6):883-90. Epub 1992/01/01. PMID: 1381103.
30. Lanctot KL, Hussey DF, Herrmann N, Black SE, Rusjan PM, Wilson AA, et al. A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2007; 15 (10):888-98. Epub 2007/06/15. doi: 10.1097/JGP.0b013e3180488325 PMID: 17567932.
31. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JA. Serotonin receptor changes in dementia of the Alzheimer type. Journal of neurochemistry. 1984; 43(6):1574-81. Epub 1984/12/01. PMID: 6208336.
32. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomolecular engineering. 2001; 17 (6):157-65. Epub 2001/05/05. PMID: 11337275.
33. Chung JA, Cummings JL. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol Clin. 2000; 18(4):829-46. Epub 2000/11/10. PMID: 11072263.
34. Filali M, Lalonde R. Motor activity in young APPswe + PS1/A246E bigenic mice as a predicting variable for memory decline. J Neurosci Res. 2015; 93(6):948-53. Epub 2015/01/17. doi: 10.1002/jnr.23552 PMID: 25594937.
35. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 2007; 6(1):54-65. doi: 10.1111/j.1601-183X.2006.00221.x PMID: 17233641
36. Lalonde R, Kim HD, Fukuchi K. Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/DeltaE9 mice. Neuroscience letters. 2004; 369(2):156-61. Epub 2004/09/29. doi: 10.1016/j.neulet.2004.07.069 PMID: 15450687.
37. Huang H, Wang L, Cao M, Marshall C, Gao J, Xiao N, et al. Isolation housing exacerbates Alzheimer's disease-like pathophysiology in aged APP/PS1 mice. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2015. Epub 2015/01/09. doi: 10.1093/ijnp/pyu116 PMID: 25568286.
38. Filali M, Lalonde R. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Research. 2009; 1292:93-9. doi: 10.1016/j.brainres.2009.07.066 PMID: 19643098
39. Filali M, Lalonde R, Rivest S. Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer's disease. Physiol Behav. 2011; 104(5):880-5. Epub 2011/06/07. doi: 10.1016/j.physbeh.2011.05.023 PMID: 21640739.
40. Kalueff AV, Tuohimaa P. Mouse grooming microstructure is a reliable anxiety marker bidirectionally sensitive to GABAergic drugs. Eur J Pharmacol. 2005; 508(1-3):147-53. Epub 2005/02/01. doi: 10.1016/j.ejphar.2004.11.054 PMID: 15680265.
41. Egashira N, Tanoue A, Matsuda T, Koushi E, Harada S, Takano Y, et al. Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice. Behav Brain Res. 2007; 178(1):123-7. Epub 2007/01/18. doi: 10.1016/j.bbr.2006.12.009 PMID: 17227684.
42. File SE, Hyde JR. Can social interaction be used to measure anxiety? British journal of pharmacology. 1978; 62(1):19-24. Epub 1978/01/01. PMID: 563752; PubMed Central PMCID: PMCPmc1667770.
43. Krsiak M, Sulcova A. Differential effects of six structurally related benzodiazepines on some ethological measures of timidity, aggression and locomotion in mice. Psychopharmacology (Berl). 1990; 101 (3):396-402. Epub 1990/01/01. PMID: 1972998.
44. Pietropaolo S, Delage P, Lebreton F, Crusio WE, Cho YH. Early development of social deficits in APP and APP-PS1 mice. Neurobiol Aging. 2012; 33(5):1002.e17-27. Epub 2011/10/22. doi: 10.1016/j. neurobiolaging.2011.09.012 PMID: 22014620.
45. Sood A, Warren Beach J, Webster SJ, Terry AV, Buccafusco JJ. The effects of JWB1-84-1 on memory-related task performance by amyloid Aβ transgenic mice and by young and aged monkeys. Neuropharmacology. 2007; 53(5):588-600. doi: 10.1016/j.neuropharm.2007.06.028 PMID: 17698153
46. Pugh PL, Richardson JC, Bate ST, Upton N, Sunter D. Non-cognitive behaviours in an APP/PS1 transgenic model of Alzheimer's disease. Behav Brain Res. 2007; 178(1):18-28. Epub 2007/01/19. doi: 10.1016/j.bbr.2006.11.044 PMID: 17229472.
47. Alexander G, Hanna A, Serna V, Younkin L, Younkin S, Janus C. Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer's disease. Behav Brain Res. 2011; 216(1):77-83. Epub 2010/07/27. doi: 10.1016/j.bbr.2010.07.016 PMID: 20655336.
48. Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Frontiers in genetics. 2014; 5:88. Epub 2014/05/06. doi: 10.3389/fgene.2014.00088 PMID: 24795750; PubMed Central PMCID: PMCPmc4005958.
49. Lalonde R, Kim HD, Maxwell JA, Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neuroscience letters. 2005; 390(2):87-92. Epub 2005/09/20. doi: 10.1016/j.neulet.2005.08.028 PMID: 16169151.
50. Ferguson SA, Sarkar S, Schmued LC. Longitudinal behavioral changes in the APP/PS1 transgenic Alzheimer's disease model. Behav Brain Res. 2013; 242:125-34. Epub 2013/01/09. doi: 10.1016/j. bbr.2012.12.055 PMID: 23295401.
51. Lok K, Zhao H, Zhang C, He N, Shen H, Wang Z, et al. Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease. Journal of the neurological sciences. 2013; 335(1-2):145-54. Epub 2013/10/08. doi: 10.1016/j.jns. 2013.09.018 PMID: 24095271.
52. Webster SJ, Bachstetter AD, Van Eldik LJ. Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease. Alzheimer's research & therapy. 2013; 5 (3):28. Epub 2013/05/28. doi: 10.1186/alzrt182 PMID: 23705774; PubMed Central PMCID: PMCPmc3706792.